Decoy Therapeutics Secures Up to $21 Million Through Private Placement Financing for Antiviral Development

Decoy Therapeutics Secures Funding for Antiviral Development

Decoy Therapeutics, Inc. (NASDAQ: DCOY), a biotechnology innovator focused on designing and developing a new class of antiviral drugs known as Designable Multi-Antivirals (D-MAVs™), has recently revealed plans for a private placement financing initiative. This deal, which is anticipated to secure up to $21 million, represents a significant step forward for the company's efforts in antiviral drug development.

Details of the Financing

On June 26, 2026, Decoy Therapeutics announced that it entered into a securities purchase agreement with a single institutional investor specializing in healthcare. This agreement, referred to as a private investment in public equity (PIPE) financing, will result in an upfront gross provision estimated at $3.5 million upon closing. The funds are earmarked for the advancement of Decoy's lead asset through key clinical trials.

The PIPE financing includes several structured components:
1. Upfront Proceeds: $3.5 million from the sale of common stock at a per-share price of $5.91.
2. Milestone-Based Warrants: Three series of warrants that could generate additional funds:
- Series A: Up to $3.5 million, contingent upon shareholder approval and the filing date for a Clinical Trial Application in Europe to start a Phase 1 clinical trial.
- Series B: Up to $7.0 million, dependent on receiving formal approval from the Medicines and Healthcare Products Regulatory Agency to conduct a Phase 2a human challenge trial in the UK.
- Series C: An additional $7.0 million contingent on public disclosure of positive data from the Phase 2a trial.
3. The overall pricing is “at-the-market,” complying with the regulations of The Nasdaq Stock Market.

The private placement arrangement is structured to respond to the dynamic needs of the company while adhering to all regulatory requirements. The funds would propel Decoy forward in its mission to develop next-generation antiviral treatments.

Using the Funds

The net proceeds from this offering will primarily facilitate the clinical progression of Decoy's lead candidates targeting various respiratory viruses. By developing these advanced therapies, Decoy aims to address the mounting health challenges posed by viral diseases globally, which have grown increasingly significant in recent years.

Harnessing the power of its proprietary IMP(3)ACT™ platform, Decoy Therapeutics employs AI-assisted design and rapid synthesis methodologies to create adaptable peptide antivirals. These breakthroughs in drug development have positioned Decoy as a leader in innovative and effective therapeutic solutions, which are critically needed in today’s rapidly evolving healthcare landscape.

Regulatory Considerations

As with any private placement financing, Decoy must navigate various regulatory frameworks. The offering relies on exemptions from registration under Section 4(a)(2) of the Securities Act and associated state securities laws. Consequently, the securities acquired through this financing route are not registered and are subject to transfer restrictions.

Furthermore, Decoy has committed to filing a registration statement with the U.S. Securities and Exchange Commission (SEC) that will cover the resale of common stock issued to the institutional investor. This action must occur within 15 calendar days following the financing closure, with a target to ascertain effectiveness of the registration within 90 days afterward if a full review by the SEC is warranted.

Future Outlook

Looking ahead, Decoy Therapeutics is poised to achieve remarkable milestones with its antiviral products. Given the urgency of developing effective antiviral options, especially in light of recent viral outbreaks, investors and stakeholders recognize the potential for Decoy’s initiatives to impact global health positively.

As Decoy proceeds with this financing, it continues its commitment to transparency and forward-thinking in drug development, aspiring to redefine the landscape of antiviral therapies. The forthcoming weeks promise to be pivotal as Decoy accelerates its operations and moves closer to clinical trial initiation, bridging the gap between innovative research and practical medical solutions.

Conclusion

In conclusion, Decoy Therapeutics is on an exciting path as it secures vital funding that will empower the company to enhance its product offerings significantly. The successful execution of this private placement will not only fuel research and development efforts but also fortify Decoy's position as a frontrunner in the biotech sector specializing in antiviral treatments.